Patients in the study were followed for six months. The company said that technical success was achieved in 98% of the patients. The side effects of fibroids such as pain and heavy menstrual bleeding were significantly reduced while the patients’ quality of life improved substantially.
Embolization is a minimally invasive procedure for uterine fibroids during which an interventional radiologist injects microspheres through a tiny catheter to the site of the fibroid. The microspheres block the blood flow to the fibroids causing them to atrophy.
Thomas Gordy, president and CEO, said: “From the beginning, CeloNova has operated on the principle that our products would give first-rate clinical outcomes for patients and meet the real-world needs of physicians. Color-coding improves patient safety while simplifying the job of those performing the procedure.”